Praxis Precision Medicines Inc (PRAX) |
|
18 -1.71 (-8.68%)
|
12-05 00:35 |
|
Open: |
19.63 |
Pre. Close: |
19.71 |
|
High:
|
19.98 |
Low:
|
17.61 |
|
Volume:
|
303,942 |
Market Cap:
|
807M |
|
|
|
|
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement Purdue Neuroscience Company; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Cambridge, Massachusetts. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
19.996 - 20.097 |
20.097 - 20.162 |
|
Low:
|
17.392 - 17.513 |
17.513 - 17.591 |
|
Close:
|
17.824 - 18.009 |
18.009 - 18.128 |
|
Technical analysis |
as of: 2021-12-03 4:46:00 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, downgraded from strong buy. Upward movement continues, but could change at any time. |
| Target: |
Six months: 23.75 One year: 26.74 |
| Support: |
Support1: 16.19 Support2: 13.47 |
| Resistance: |
Resistance1: 20.33 Resistance2: 22.89 |
| Pivot: |
18.22 |
| Moving Average: |
MA(5): 17.81  MA(20): 18.94
MA(100): 18.80 MA(250): 28.95 |
| MACD: |
MACD(12,26): -0.71 Signal(9): -0.70 |
| Stochastic oscillator: |
%K(14,3): 43.09 %D(3): 30.42 |
| RSI: |
RSI(14): 44.49 |
| 52-week: |
High: 60.95 Low: 12.71 Change(%): -59.4 |
| Average Vol(K): |
3-Month: 23224 10-Days: 33411 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.PRAX has closed above bottom band by 44.3%. Bollinger Bands are 18.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Thu, 02 Dec 2021
Will Praxis Precision Medicines Inc (PRAX) Outperform the Rest of the Stocks in the Healthcare Sector? - InvestorsObserver
Mon, 29 Nov 2021
Praxis Precision Medicines to Present Data from Rare Disease Programs at the American Epilepsy Society 2021 Annual Meeting - GlobeNewswire
Wed, 24 Nov 2021
Praxis Precision Medicines to Present at Piper Sandler's 33rd Annual Virtual Healthcare Conference - The Bakersfield Californian
Wed, 03 Nov 2021
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2021 Financial Results - Yahoo Finance
Wed, 01 Sep 2021
Praxis Precision Medicines to Present at Citi's 16th Annual - GlobeNewswire
Mon, 16 Aug 2021
Praxis Precision Medicines Shares Drop 6% After Results for Depression Treatment - MarketWatch
|
Financial Analysis |
| Growth |
NA |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
NA |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
NA |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
NA |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
45 |
| Shares Float (M) |
35 |
|
% Held by Insiders
|
1.43 |
|
% Held by Institutions
|
94.11 |
|
Shares Short (K)
|
1,420 |
|
Shares Short P. Month (K)
|
1,360 |
Stock Financials |
|
EPS
|
-3.470 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
6.660 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-37.8 |
|
Return on Equity (ttm)
|
-66.3 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-2.993 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-100 |
|
Levered Free Cash Flow (M)
|
-53 |
Stock Valuations |
|
PE Ratio
|
-5.19 |
|
PEG Ratio
|
|
|
Price to Book value
|
2.70 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-8.08 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
